By Josh Beckerman
Inovio Pharmaceuticals shares were down 20% to $2.99 after hours as the company said it plans to sell stock and accompanying warrants.
The company intends to use proceeds primarily for the development of its clinical pipeline, including preparing for a potential commercial launch of lead drug candidate INO-3107 if approved, and for general corporate purposes. INO-3107 is a potential treatment for recurrent respiratory papillomatosis, a benign tumor disease.
In August, Inovio filed a prospectus supplement for the potential sale of up to $60 million of stock from time to time. On April 15, it announced the pricing of a roughly $36 million offering.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
December 12, 2024 18:49 ET (23:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。